Modality
Gene Editing
MOA
CD3xCD20
Target
USP1
Pathway
Epigenetic
Ewing Sarcoma
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
~Mar 2018
→ ~Jun 2019
Phase 3
~Sep 2019
→ ~Dec 2020
NDA/BLA
~Mar 2021
→ ~Jun 2022
Approved
Sep 2022
→ Sep 2028
ApprovedCurrent
NCT07044952
1,177 pts·Ewing Sarcoma
2022-09→2028-09·Active
1,177 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-09-092.4y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Active
Catalysts
Ph3 Readout
2028-09-09 · 2.4y away
Ewing Sarcoma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07044952 | Approved | Ewing Sarcoma | Active | 1177 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Cevizasiran | Acadia Pharma | Phase 1/2 | GPRC5D | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 | |
| Tezesotorasib | Enliven | Phase 2 | USP1 |